AAHRPP-Accredited IRB Review for Oncology Clinical Trials
Oncology protocols are among the most complex documents that IRBs review. Novel mechanisms of action, unfamiliar risk profiles, combination regimens, and adaptive designs require IRB reviewers with genuine oncology literacy — not just procedural familiarity with consent and protocol structure.
Sitero operates an AAHRPP-accredited IRB with experience reviewing oncology protocols across a range of indications and trial designs. AAHRPP accreditation reflects the highest standard of human research protections and is recognized by sponsors and regulators as a mark of institutional rigor.
The Complexity of Oncology Protocol Review
An oncology IRB review is not primarily a paperwork exercise. Reviewers need to assess the scientific rationale for the proposed risk-benefit profile, evaluate whether the consent document accurately represents what patients are agreeing to, and consider whether eligibility criteria are appropriately protective for a vulnerable population. For early-phase trials involving novel agents or combination regimens, this requires reviewers who understand oncology development.
Protocol Amendments and Re-Review
Oncology trials amend frequently. Each substantive amendment requires IRB review and approval before implementation. For sponsors managing active trials, the speed and predictability of the amendment review process directly affect operational timelines. Sitero’s remote protocol management capabilities and flexible committee operations are designed to provide responsive review turnaround without sacrificing rigor.
Reducing Administrative Drag
Beyond the review itself, the administrative overhead of IRB interaction — submission preparation, correspondence management, continuing review tracking — consumes meaningful time for sponsor and site teams. Sitero’s IRB consulting services help sponsors prepare submissions efficiently, reducing the back-and-forth that delays initial approval and amendment implementation.
Integration with Clinical Operations
For sponsors using Sitero as both CRO and IRB, the coordination between protocol review and site activation is managed under one operational model. This eliminates the handoff delays between IRB approval and site initiation that add weeks to startup timelines under a fragmented vendor model — a contributing factor to the 40% reduction in startup timelines Sitero’s oncology programs have documented.
Supporting Early-Phase Oncology Review
Early-phase oncology protocols — particularly first-in-human studies and dose escalation designs — present IRBs with risk-benefit assessments that require scientific depth alongside standard ethical review criteria. Sitero’s IRB committee operations are structured to support this level of review, with access to medical expertise relevant to the scientific and clinical context of the submission.
Frequently Asked Questions
AAHRPP accreditation is the highest standard of recognition for human research protection programs. For oncology sponsors, it means Sitero’s IRB operates under a rigorous, externally audited quality framework — which supports regulatory submissions and reflects the governance standard expected for complex oncology protocols.
Sitero’s IRB offers remote protocol management and flexible committee operations designed to support responsive amendment review turnaround. Sponsors managing active oncology trials with frequent amendments can expect predictable review timelines without the delays common to busier institutional IRBs.
Yes. When Sitero serves as both CRO and IRB, the coordination between protocol review, site activation, and operational startup is managed under one model. This eliminates handoff delays between governance and operations and contributes to the startup timeline reductions Sitero’s oncology programs have documented.
